Bill Posted May 25, 2005 Share Posted May 25, 2005 http://www.massgeneral.org/pubaffairs/i ... 5Haber.htm Quote Link to comment Share on other sites More sharing options...
tnmynatt Posted May 25, 2005 Share Posted May 25, 2005 Thanks for the info. I'm going to keep my eyes open for further developments. Take care. Quote Link to comment Share on other sites More sharing options...
john Posted May 25, 2005 Share Posted May 25, 2005 The trial is at Mass General One of the irreversible EGFR inhibitors used in this study – HKI-272, manufactured by Wyeth – is already in a phase 1 clinical trial. And MGH Cancer Center researchers are planning to lead a multi-institutional phase 2 trial in NSCLC patients whose tumors have sensitizing EGFR mutations but have become resistant to Iressa or Tarceva. http://www.eurekalert.org/pub_releases/ ... 051105.php Quote Link to comment Share on other sites More sharing options...
Fay A. Posted May 25, 2005 Share Posted May 25, 2005 Thank you for posting the info, Bill. Quote Link to comment Share on other sites More sharing options...
Lisa O Posted May 26, 2005 Share Posted May 26, 2005 Every new development is a sign of hope! Thanks. Quote Link to comment Share on other sites More sharing options...
john Posted May 26, 2005 Share Posted May 26, 2005 Other irreversible inhibitors are EKB-569 and CI-1033. CI-1033 is also a pan-EGFR inhibitor which means in inihibits 3 growth factors not just one Quote Link to comment Share on other sites More sharing options...
endangered but surviving Posted May 30, 2005 Share Posted May 30, 2005 You guys are incredible. How you keep on top of everything and keep at it, I get overwhelmed every time I come to this site. Thanks. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.